Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.
A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis,” published in the November 2024 issue of Dermatology by Ferris et al.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback